Clinical Trial Update: TYSABRI Global Observational Program in Safety

View source ↗

Summary

Global observational safety program for TYSABRI (natalizumab) has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• Tysabri (Natalizumab)

Snippet

Sponsor: Biogen | Conditions: Multiple Sclerosis | Status: COMPLETED